Summit Therapeutics (SMMT) Operating Leases (2018 - 2026)
Summit Therapeutics' (SMMT) quarterly Operating Leases came in at $16.8 million in Q2 2026, up 591.33% YoY from $2.4 million in Q2 2025, and little changed on a QoQ basis from $16.9 million in Q1 2026.
Summit Therapeutics (SMMT) Operating Leases (2018 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 9 years of Operating Leases data on file, last reported at $16.8 million in Q2 2026.
- Quarterly Operating Leases rose 591.33% year-over-year to $16.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $16.8 million (up 591.33% YoY) and the FY2025 annual result came in at $17.5 million, up 406.86% from the prior year.
- Operating Leases held at $16.8 million in Q2 2026, from $16.9 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $17.5 million in Q4 2025 to a low of $1.3 million in Q2 2022.
- A 5-year average of $5.6 million and a median of $3.4 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2025 — Operating Leases tumbled 51.47% — and 2026, when it soared 591.33%.
- Tracing SMMT's Operating Leases over 5 years: stood at $2.8 million in 2022, then advanced by 19.07% to $3.3 million in 2023, then rose by 4.95% to $3.5 million in 2024, then jumped by 406.86% to $17.5 million in 2025, then declined by 3.82% to $16.8 million in 2026.
- The last three Operating Leases figures came in at $16.8 million (Q2 2026), $16.9 million (Q1 2026), and $17.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.83 Mn |
| Mar 31, 2026 | 16.86 Mn |
| Dec 31, 2025 | 17.50 Mn |
| Sep 30, 2025 | 2.71 Mn |
| Jun 30, 2025 | 2.44 Mn |
| Mar 31, 2025 | 2.91 Mn |
| Dec 31, 2024 | 3.45 Mn |
| Sep 30, 2024 | 4.21 Mn |
| Jun 30, 2024 | 5.02 Mn |
| Mar 31, 2024 | 5.82 Mn |
| Dec 31, 2023 | 3.29 Mn |
| Sep 30, 2023 | 3.88 Mn |
| Jun 30, 2023 | 4.33 Mn |
| Mar 31, 2023 | 2.49 Mn |
| Dec 31, 2022 | 2.76 Mn |
| Sep 30, 2022 | 2.97 Mn |
| Jun 30, 2022 | 1.32 Mn |
| Mar 31, 2022 | 1.54 Mn |
| Dec 31, 2021 | 1.69 Mn |
| Sep 30, 2021 | 896,000.00 |